Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
2cureX ABFRA:2QE +0.38%37 EPS without NRI is €-0.08 as of Jun. 2025. GuruFocus rates FRA:2QE with a GF Score™ of 37/100. The stock has 3 warning signs investors should review. Among 1,167 Biotechnology companies, 2cureX AB ranks better than 82.09% on this metric.
2cureX AB's earnings per share without non-recurring items for the
six
months ended in Jun. 2025 was €-0.07.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2025 was €-0.08.
During the past 3 years, the average earnings per share (NRI) Growth Rate was 46.00% per year.
During the past 5 years, the average earnings per share (NRI) Growth Rate was 5.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for 2cureX AB's EPS without NRI or its related term are showing as below:
FRA:2QE'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -151.5 Med: -35.5 Max: 46
Current: 46
During the past 10 years, 2cureX AB's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 46.00% per year. The lowest was -151.50% per year. And the median was -35.50% per year.
FRA:2QE's 3-Year EPS without NRI Growth Rate is ranked better than 82.09% of 1167
companies
in the Biotechnology industry
Industry Median: 16.6
vs FRA:2QE: 46.00
2cureX AB's EPS (Diluted) for the
six
months ended in Jun. 2025 was €-0.07.
Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2025 was €-0.08.
2cureX AB's EPS (Basic) for the
six
months ended in Jun. 2025 was €-0.07.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2025 was €-0.08.
2cureX AB (FRA:2QE) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
2cureX AB EPS without NRI Related Terms
2cureX AB EPS without NRI Historical Data
* Premium members only.
The historical data trend for 2cureX AB's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:2QE vs VRTX, REGN, ALNY: EPS without NRI Comparison
For the Biotechnology subindustry, 2cureX AB's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
2cureX AB PE Ratio without NRI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, 2cureX AB's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where 2cureX AB's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.08
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
2cureX AB (FRA:2QE) has a EPS without NRI of €-0.08 as of Jun. 2025. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on 2cureX AB and its competitors. According to the industry distribution chart, 2cureX AB ranks #209 out of 1167 companies in the Biotechnology industry, placing it in the top 17.9%.
Is 2cureX AB's EPS without NRI too high?
2cureX AB's current EPS without NRI is €-0.08. Based on the distribution chart, 2cureX AB ranks #209 out of 1167 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, 2cureX AB has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does 2cureX AB's EPS without NRI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, 2cureX AB ranks #209 out of 1167 companies for EPS without NRI. This places 2cureX AB in the top 18% of its industry — outperforming the majority of peers. The industry median EPS without NRI is 16.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Biotechnology company?
The median EPS without NRI among Biotechnology companies is 16.60, based on 1,167 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on 2cureX AB and its competitors. For the Biotechnology industry, the median EPS without NRI is 16.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 2cureX AB's current EPS without NRI is €-0.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 2cureX AB stock overvalued right now?
2cureX AB (FRA:2QE) has a current EPS without NRI of €-0.08. The current EPS without NRI is €-0.08. 2cureX AB's overall GF Score™ is 37/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For 2cureX AB (FRA:2QE), the current EPS without NRI is €-0.08 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
2cureX AB is a biotech company. The company is engaged in improving treatment efficiency, mainly for cancer patients. It is involved in developing a product, namely IndiTreat, which is a technology for the treatment of colorectal, ovarian, and pancreatic cancers. The company's sub-products include IndiTreat Test, IndiTreat clinical programs, and IndiTreat Therapy Design.
37GF Score
Get the complete analysis for FRA:2QE
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2QE has been successfully added to your 
